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Background:  Troponin assays have evolved and become increasingly more sensitive. The prognostic value of identifying small elevations of plasma 
troponin concentrations in patients with suspected acute coronary syndrome remains uncertain.
Methods: We performed a retrospective observational study of 1,038 consecutive patients admitted with suspected acute coronary syndrome 
during the validation of a sensitive troponin I assay. Patients were stratified into three groups based on plasma troponin concentrations: <0.05, 
0.05-0.19 and >0.20 ng/mL. During this validation phase, only concentrations above the previous diagnostic threshold of >0.20 ng/mL were 
reported to clinicians.
Results: Plasma troponin concentrations were <0.05 ng/mL in 657 (63%), 0.05-0.19 ng/mL in 90 (9%) and >0.20 ng/mL in 291 (28%) patients. 
In comparison to patients with a troponin concentration >0.20 ng/mL, those with a concentration of 0.05-0.19 ng/mL were less likely to be referred 
to a cardiologist (44 versus 93%), to receive dual anti-platelet therapy (27 versus 80%), or to undergo coronary revascularisation (17 versus 59%) 
(P<0.001 for all). At one year, 39% of patients with plasma troponin concentrations of 0.05-0.19 ng/mL were dead or had been readmitted with 
recurrent myocardial infarction, compared to 7% and 24% of patients with troponin concentration of <0.05 ng/mL (P<0.001) or >0.20 ng/mL 
(P=0.007) respectively.
Conclusions: In patients with suspected acute coronary syndrome, use of a sensitive troponin assay markedly increases the incidence of 
myocardial infarction and identifies those at high-risk of reinfarction and death. Its use will lead to major changes in practice with the potential for 
reduced morbidity and mortality.
